Dyne Therapeutics annual working capital
2019
2020
2021
2022
2023
2024
2025
Dyne Therapeutics Working Capital Growth & History (DYN)
Dyne Therapeutics's working capital was $1.08B for fiscal 2025.
View full Dyne Therapeutics company overviewDyne Therapeutics annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.08B | $458.9M | +74.38% |
| 2024 | 2024-12-31 | $617.0M | $538.7M | +688.22% |
| 2023 | 2023-12-31 | $78.3M | −$159.2M | −67.04% |
| 2022 | 2022-12-31 | $237.5M | −$116.2M | −32.85% |
| 2021 | 2021-12-31 | $353.7M | $15.5M | +4.60% |
| 2020 | 2020-12-31 | $338.1M | $325.7M | +2626.55% |
| 2019 | 2019-12-31 | $12.4M | — | — |
Dyne Therapeutics quarterly working capital
Q4.19
Q3.20
Q4.20
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $859.9M | $203.4M | +30.98% |
| Q1 2026 | 2026-03-31 | $969.8M | $314.2M | +47.92% |
| Q4 2025 | 2025-12-31 | $1.08B | $458.9M | +74.38% |
| Q3 2025 | 2025-09-30 | $746.4M | $53.3M | +7.69% |
| Q2 2025 | 2025-06-30 | $656.5M | −$106.1M | −13.91% |
| Q1 2025 | 2025-03-31 | $655.6M | $189.8M | +40.76% |
| Q4 2024 | 2024-12-31 | $617.0M | $538.7M | +688.22% |
| Q3 2024 | 2024-09-30 | $693.1M | $554.6M | +400.37% |
| Q2 2024 | 2024-06-30 | $762.6M | $569.6M | +295.21% |
| Q1 2024 | 2024-03-31 | $465.8M | $238.2M | +104.62% |
| Q4 2023 | 2023-12-31 | $78.3M | −$159.2M | −67.04% |
| Q3 2023 | 2023-09-30 | $138.5M | −$96.4M | −41.03% |
| Q2 2023 | 2023-06-30 | $193.0M | −$79.4M | −29.14% |
| Q1 2023 | 2023-03-31 | $227.6M | −$93.6M | −29.14% |
| Q4 2022 | 2022-12-31 | $237.5M | −$116.2M | −32.85% |
| Q3 2022 | 2022-09-30 | $234.9M | −$166.4M | −41.46% |
| Q2 2022 | 2022-06-30 | $272.3M | — | — |
| Q1 2022 | 2022-03-31 | $321.2M | — | — |
| Q4 2021 | 2021-12-31 | $353.7M | $15.5M | +4.60% |
| Q3 2021 | 2021-09-30 | $401.3M | $26.1M | +6.97% |
| Q4 2020 | 2020-12-31 | $338.1M | $325.7M | +2626.55% |
| Q3 2020 | 2020-09-30 | $375.2M | — | — |
| Q4 2019 | 2019-12-31 | $12.4M | — | — |
Dyne Therapeutics working capital trends
Over the last five fiscal years, Dyne Therapeutics's working capital increased from $338.1M to $1.08B, a change of $737.8M. The latest reported quarter, Q2 2026, shows $859.9M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dyne Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...